← All Seaport Therapeutics, INC filings

Seaport Therapeutics, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NASDAQ
SPTX
Seaport Therapeutics, INC
8-K: Seaport Therapeutics Reports Q3 2026 Results, Clinical Milestones
Seaport Therapeutics announced third quarter 2026 financial results, highlighting positive topline data from a Phase 1 driving trial for GlyphAllo and the dosing of the first patient in a Phase 2a trial for GlyphAgo.
NASDAQ
SPTX
Seaport Therapeutics, INC
8-K: Seaport Therapeutics Reports Q2 2026 Results, Advances Pipeline
Seaport Therapeutics announced its second quarter 2026 financial results, detailing progress in its clinical trials for major depressive disorder and generalized anxiety disorder, alongside a robust cash position post-IPO.